FGF23 and diabetic kidney disease: Concerning DKD, a case control study of patients enrolled in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial demonstrated that baseline serum FGF23 levels did not predict the CKD incidence in 590 T2D patients [36].